Biotecnol, Inc. is developing the next generation of antibody-based therapeutics for the treatment of diseases in a vast number of therapeutic areas and indications based on its proprietary Tribody™ technology.

Tribody molecules are multi-specific antibody products which utilize the natural in vivo heterodimerization of Fab fragments to form a scaffold, upon which additional proteins can be incorporated. As a result Tribodies are characterized by an unsurpassed versatility; they can incorporate up to three different binders and combine different and novel functions, such as T-cell recruitment and dual targeting, in a single molecule. This new format for T-cell recruiting antibodies has demonstrated superior therapeutic performances both in vitro and in vivo.